Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M79,890Revenue $M19,616Net Margin (%)11.2Z-Score3.9
Enterprise Value $M82,688EPS $2.2Operating Margin %16.0F-Score4
P/E(ttm))35.1Cash Flow Per Share $5.4Pre-tax Margin (%)13.9Higher ROA y-yN
Price/Book5.210-y EBITDA Growth Rate %10.8Quick Ratio1.1Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %-6.0Current Ratio1.4Lower Leverage y-yN
Price/Cash Flow9.1y-y EBITDA Growth Rate %-32.9ROA % (ttm)6.2Higher Current Ratio y-yN
Dividend Yield %2.7Insider Buy (3m)0ROE % (ttm)13.0Less Shares Outstanding y-yY
Payout Ratio %96.0Shares Outstanding M1,110ROI % (ttm)23.7Gross Margin Increase y-yN

Gurus Latest Trades with LLY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LLYVanguard Health Care Fund 2015-03-31 Add0.45%$68.41 - $76.36
($71.19)
$ 73.053%Add 13.24%24,892,160
LLYKen Fisher 2015-03-31 Add0.03%$68.41 - $76.36
($71.19)
$ 73.053%Add 37.46%795,909
LLYMario Gabelli 2015-03-31 Reduce$68.41 - $76.36
($71.19)
$ 73.053%Reduce -1.76%111,800
LLYCharles Brandes 2014-12-31 Reduce-1.85%$61.9 - $72.83
($67.53)
$ 73.058%Reduce -92.65%169,348
LLYRichard Pzena 2014-12-31 Sold Out -0.15%$61.9 - $72.83
($67.53)
$ 73.058%Sold Out0
LLYKen Fisher 2014-12-31 Add0.07%$61.9 - $72.83
($67.53)
$ 73.058%Add 383.26%578,992
LLYCharles Brandes 2014-09-30 Reduce-0.29%$60.35 - $66.59
($63.3)
$ 73.0513%Reduce -14.27%2,303,062
LLYHOTCHKIS & WILEY 2014-09-30 Reduce-0.12%$60.35 - $66.59
($63.3)
$ 73.0513%Reduce -10.92%4,321,666
LLYGeorge Soros 2014-09-30 Sold Out -0.02%$60.35 - $66.59
($63.3)
$ 73.0513%Sold Out0
LLYKen Fisher 2014-09-30 Add0.02%$60.35 - $66.59
($63.3)
$ 73.0513%Add 2742.47%119,810
LLYDavid Dreman 2014-09-30 Reduce-0.02%$60.35 - $66.59
($63.3)
$ 73.0513%Reduce -84.40%900
LLYDodge & Cox 2014-09-30 Add$60.35 - $66.59
($63.3)
$ 73.0513%Add 20.38%42,464
LLYJoel Greenblatt 2014-09-30 Reduce$60.35 - $66.59
($63.3)
$ 73.0513%Reduce -27.37%5,628
LLYHOTCHKIS & WILEY 2014-06-30 Add0.73%$58.21 - $63.1
($59.62)
$ 73.0518%Add 199.70%4,851,480
LLYVanguard Health Care Fund 2014-06-30 Reduce-0.15%$58.21 - $63.1
($59.62)
$ 73.0518%Reduce -3.98%21,982,700
LLYGeorge Soros 2014-06-30 Buy 0.02%$58.21 - $63.1
($59.62)
$ 73.0518%New holding50,441
LLYHOTCHKIS & WILEY 2014-03-31 Buy 0.35%$50.73 - $59.85
($55.61)
$ 73.0524%New holding1,618,802
LLYJoel Greenblatt 2014-03-31 Reduce-0.16%$50.73 - $59.85
($55.61)
$ 73.0524%Reduce -93.61%9,016
LLYVanguard Health Care Fund 2013-12-31 Add0.67%$47.65 - $51.34
($50.05)
$ 73.0531%Add 22.98%22,895,000
LLYCharles Brandes 2013-12-31 Add0.19%$47.65 - $51.34
($50.05)
$ 73.0531%Add 12.57%2,711,949
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LLY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


LLY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LILLY ENDOWMENT INC10% Owner 2015-03-30Sell180,000$73.94-1.11view
LILLY ENDOWMENT INC10% Owner 2015-03-23Sell190,000$76.97-5view
Fry Stephen FSVP, HR & Diversity 2015-03-09Sell4,000$69.275.56view
Zakrowski Donald AChief Accounting Officer 2015-02-05Sell374$71.032.94view
Rice Derica WEVP-Global Services and CFO 2015-02-04Sell5,316$704.46view
Lundberg Jan MEVP,Science&Tech and Pres. LRL 2015-02-04Sell11,085$70.084.34view
Ricks David ASVP and Pres, Lilly Bio-Meds 2015-02-04Sell3,147$69.994.47view
Lundberg Jan MEVP,Science&Tech and Pres. LRL 2015-02-03Sell121,711$70.783.31view
Rice Derica WEVP-Global Services and CFO 2015-02-02Sell10,068$71.841.78view
Ricks David ASVP and Pres, Lilly Bio-Meds 2015-02-02Sell4,769$71.512.25view

Press Releases about LLY :

    Quarterly/Annual Reports about LLY:

    News about LLY:

    Articles On GuruFocus.com
    Biogen Making A Breakthrough In Treating Alzheimer’s May 02 2015 
    MannKind Looks Good For Long Term Investors Apr 29 2015 
    What Are The Intrinsic Factors Contributing To Pfizer’s Stock Movement? Mar 27 2015 
    Eli Lilly Inks Major Deal In China To Develop Oncology Segment Mar 23 2015 
    Box Inc. Declares Mixed Bag Q4 Results for 2015 Mar 13 2015 
    Primecap Management's Annual Shareholder Letter 2014 Mar 09 2015 
    FDA Approves Sanofi’s New Diabetes Drug Feb 27 2015 
    Feeling Good With This Med Company Jan 20 2015 
    Sarah Ketterer Dives in when Others Pull Out Nov 14 2014 
    Weekly 52-Week Highs Highlight: LLY, BG, NVS, HRL Sep 07 2014 

    More From Other Websites
    Lilly to Participate in Bank of America Merrill Lynch Health Care Conference May 01 2015
    Lilly to Participate in Bank of America Merrill Lynch Health Care Conference May 01 2015
    LILLY ELI & CO Files SEC form 10-Q, Quarterly Report Apr 30 2015
    Eli Lilly (LLY) Stock Rising Following Citigroup Upgrade Apr 29 2015
    IPO Outlook: CoLucid Offers Hope For Migraine Sufferers Apr 29 2015
    Eli Lilly upgraded by Citigroup Apr 29 2015
    Japan's Takeda agrees to pay $2.4 bln in diabetes drug suit Apr 29 2015
    Japan's Takeda agrees to pay $2.4 bln in diabetes drug suit Apr 29 2015
    Takeda warns of loss after $2.4 bn diabetes drug settlements Apr 28 2015
    Takeda to pay $2.7bn to settle Actos cancer claims Apr 28 2015
    Takeda agrees $2.4 bn settlement for diabetes drug suits Apr 28 2015
    Salesforce.com CEO: Focused on stakeholders Apr 28 2015
    Takeda warns of loss after $2.4 bn diabetes drug settlements Apr 28 2015
    Takeda agrees $2.4 bn settlement for diabetes drug suits Apr 28 2015
    Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As... Apr 28 2015
    Takeda Said to Agree to Pay $2.3 Billion to Settle Actos Cases Apr 27 2015
    Eli Lilly's Cyramza Gains FDA Approval for Label Expansion - Analyst Blog Apr 27 2015
    3 Surprising Overlooked Stocks That Could Have Big Upside Apr 27 2015
    Abbott Laboratories (ABT) Earnings Analysis: By the Numbers Apr 24 2015
    Lilly's CYRAMZA® (ramucirumab) Receives Fourth FDA Approval Apr 24 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK